Median Technologies has reported strong full-year 2025 financial results, showcasing significant growth in their oncology-focused AI diagnostic platform. The company’s fourth-quarter revenue increased 23% compared to the previous year, driven by expanded hospital partnerships and increased adoption of their cancer detection software across European markets.
For Q1 2026, Median highlighted key business developments including a major partnership with a leading pharmaceutical company to integrate their diagnostic tools into clinical trial workflows. The company also announced FDA breakthrough device designation for their lung cancer screening algorithm, positioning them for accelerated market entry in the United States.
Looking ahead, Median projects continued revenue growth through strategic international expansion and new product launches. Their AI-powered diagnostic solutions are gaining traction among healthcare providers seeking to improve early cancer detection rates while reducing diagnostic turnaround times.
Source: Read original article
